Innovation Pharmaceuticals Inc (IPIX)

[Patientspeople]

Outstanding Results! We're Talking PREVENTION of Severe OM - these results are impressive! 63.2% of patients in the Per Protocol Population (PP) didn't suffer through Severe OM vs. the majority of patients in the placebo arm having to suffer with Severe OM. This is a new era, Oncologists and Radiation Oncologists will now have a proactive therapy to reduce the likelihood and or severity of a terribly painful and debilating condition SEVERE Oral Mucositis that is a very high unmet need by currently available options. It's a great advancement for the treatment of OM. I would expect that these top line results will lead to a partnership and a big surge in stock value due to the untapped Billion dollar market for OM.

Ask yourself, wouldn't you demand Brilacidin therapy for yourself or someone you know as a preventitive easy to administer therapy if you knew the likely hood for OM was high?

"Summary of Topline Results from the Placebo-Controlled Phase 2 Trial"

Brilacidin met primary endpoint of reduced incidence of severe OM experienced by patients during radiation therapy.

Incidence of severe OM in Modified Intent to Treat (mITT) Population: Brilacidin 42.9%, Placebo 60.0%.

Incidence of severe OM in Per Protocol (PP) Population: Brilacidin 36.8%, Placebo 60.0%.

Trial results support continued and expedited development of Brilacidin-OM.